L3Harris Nears $500M Deal to Sell Majority Stake in Space Propulsion Portfolio to AE Industrial 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Tesla Poised for Breakout Year in 2026 as New Products and EV Market Reset Drive Growth 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Kia Targets 3.35 Million Global Vehicle Sales in 2026 Amid Steady Growth Outlook 
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Samsung Electronics Hits Record High as AI Momentum Fuels Investor Optimism 
Trump Blocks HieFo’s Emcore Chip Assets Deal Over National Security Concerns 
VANCOUVER, British Columbia, March 14, 2017 -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main, President & CEO, will provide a corporate update at the upcoming Oppenheimer & Co. 27th Annual Healthcare Conference in New York on Wednesday, March 22nd 2017.
Aquinox Presentation Details
Date: Wednesday, March 22nd 2017
Time: 9:45 am Eastern Time / 6:45 am Pacific Time
Location: New York, NY – Westin New York Grand Central
A live audio webcast and archive of the event will be available at:
https://www.veracast.com/webcasts/opco/healthcare2017/05203513909.cfm
To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on the Investor Relations page of the Aquinox website. The corporate overview being presented will be available following the presentation at www.aqxpharma.com.
About Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a late clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Our primary focus is anti-inflammatory product candidates targeting SH2-containing inositol-5'-phosphatase 1, or SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. Aquinox's lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. In September 2016, we began enrolling patients in a Phase 3 clinical trial of AQX-1125 in our lead indication, Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). Other indications are under consideration for future investigation. Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1. For more information, please visit www.aqxpharma.com.
Investor Contact Info:
Brendan Payne
Senior Manager, Investor Relations
Aquinox Pharmaceuticals, Inc.
604.901.3019
[email protected]
Gitanjali Ogawa
Vice President
The Trout Group
646-378-2949
[email protected]
